176 related articles for article (PubMed ID: 6101934)
21. Metoprolol in angina pectoris complicated by essential hypertension. A clinical comparison of the antianginal efficacy of metoprolol slow-release tablets (Durules) given once daily and propranolol tablets given twice daily.
BLoem TJ; Lindner PC
Ann Clin Res; 1981; 13 Suppl 30():61-7. PubMed ID: 6794420
[TBL] [Abstract][Full Text] [Related]
22. Comparison of metoprolol and verapamil in the treatment of angina pectoris.
Arnman K; Rydén L
Am J Cardiol; 1982 Mar; 49(4):821-7. PubMed ID: 6801951
[TBL] [Abstract][Full Text] [Related]
23. Effects of the cardioselective beta-adrenergic receptor blocking agent metoprolol in angina pectoris. Subacute study with exercise tests.
Ekelund LG; Olsson AG; Orö L; Rössner S
Br Heart J; 1976 Feb; 38(2):155-61. PubMed ID: 4080
[TBL] [Abstract][Full Text] [Related]
24. Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade.
McDevitt DG; Brown HC; Carruthers SG; Shanks RG
Clin Pharmacol Ther; 1977 May; 21(5):556-66. PubMed ID: 15753
[TBL] [Abstract][Full Text] [Related]
25. Comparison of clinical effects of propranolol (Inderal) with once daily slow-release oxprenolol (Slow Trasicor) in angina pectoris.
Majid PA; de Feijter PJ; Wardeh R; van der Wall EE; Roos JP
J Int Med Res; 1979; 7(3):194-200. PubMed ID: 378729
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the effects of two doses of bisoprolol on exercise tolerance in exercise-induced stable angina pectoris.
de Muinck E; Wagner G; vd Ven LL; Lie KI
Eur Heart J; 1987 Dec; 8 Suppl M():31-5. PubMed ID: 2897300
[TBL] [Abstract][Full Text] [Related]
27. The effect of timolol vs placebo on angina pectoris.
Aronow WS; Turbow M; Van Camp S; Lurie M; Whittaker K
Circulation; 1980 Jan; 61(1):66-9. PubMed ID: 6765920
[TBL] [Abstract][Full Text] [Related]
28. Beta adrenergic blocking agents for exertional angina pectoris.
Thadani U
Herz; 1982 Jun; 7(3):179-87. PubMed ID: 6124493
[TBL] [Abstract][Full Text] [Related]
29. Calcium channel blockade as primary therapy for stable angina pectoris. A double-blind placebo-controlled comparison of verapamil and propranolol.
Subramanian VB; Bowles MJ; Davies AB; Raftery EB
Am J Cardiol; 1982 Nov; 50(5):1158-63. PubMed ID: 6127945
[TBL] [Abstract][Full Text] [Related]
30. [Double-blind, placebo-controlled trial of propranolol vs celiprolol in stable effort angina: antianginal efficacy and side effects ].
Klein W; Fluch N; Brandt D
Wien Klin Wochenschr; 1982 May; 94(10):258-61. PubMed ID: 6126961
[TBL] [Abstract][Full Text] [Related]
31. A new water-soluble, selective beta-blocker with intrinsic sympathomimetic activity (ICI 141.292) in angina pectoris.
Erikssen J; Rollag A; Otterstad JE
Acta Med Scand; 1988; 223(1):35-43. PubMed ID: 2894747
[TBL] [Abstract][Full Text] [Related]
32. Comparison of adrenergic beta-blocking drugs in angina pectoris.
Sharma B; Meeran MK; Galvin MC; Tulpule AT; Whitaker W; Taylor SH
Br Med J; 1971 Jul; 3(5767):152-5. PubMed ID: 4397655
[TBL] [Abstract][Full Text] [Related]
33. Nadolol compared to propranolol for treating chronic stable angina pectoris.
Miller LA; Crawford MH; O'Rourke RA
Chest; 1984 Aug; 86(2):189-93. PubMed ID: 6146499
[TBL] [Abstract][Full Text] [Related]
34. [Effect of metoprolol on the exercise tolerance in patients with stable angina pectoris (author's transl)].
Tomei G; Mosti G; Veltri M; Giusti C
G Ital Cardiol; 1978; 8(12):1286-92. PubMed ID: 367865
[TBL] [Abstract][Full Text] [Related]
35. Anti-anginal and anti-ischemic effects of the selective beta-blocker talinolol in patients with stable angina pectoris.
Faulhaber HD; Weigmann I; Lang U; Weinsberg F; Terhaag B
Int J Clin Pharmacol Ther; 2005 Feb; 43(2):63-70. PubMed ID: 15726874
[TBL] [Abstract][Full Text] [Related]
36. Pindolol and propranolol in patients with angina pectoris and normal or near-normal ventricular function. Lack of influence of intrinsic sympathomimetic activity on global and segmental left ventricular function assessed by radionuclide ventriculography.
Manyari DE; Kostuk WJ; Carruthers SG; Johnston DJ; Purves P
Am J Cardiol; 1983 Feb; 51(3):427-33. PubMed ID: 6401908
[TBL] [Abstract][Full Text] [Related]
37. The effects of a new adrenergic blocking agent (K4423) on exercise tolerance in angina pectoris.
Libretti A; Gregorini L; Valentini R
Cardiology; 1973; 58(6):369-75. PubMed ID: 4153721
[No Abstract] [Full Text] [Related]
38. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris.
Thadani U; Zellner SR; Glasser S; Bittar N; Montoro R; Miller AB; Chaitman B; Schulman P; Stahl A; DiBianco R
Circulation; 1991 Dec; 84(6):2398-408. PubMed ID: 1959195
[TBL] [Abstract][Full Text] [Related]
39. Comparison of once and twice daily oral dosing schedules of bevantolol, a new beta-adrenoceptor antagonist with alpha-adrenoceptor partial antagonist activity in patients with angina of effort.
Molajo AO; Bray CL; Hillier V
Int J Cardiol; 1989 Nov; 25(2):185-92. PubMed ID: 2572566
[TBL] [Abstract][Full Text] [Related]
40. A comparison of nine calcium ion antagonists and propranolol: exercise tolerance, heart rate and ST-segment changes in patients with chronic stable angina pectoris.
Khurmi NS; Raftery EB
Eur J Clin Pharmacol; 1987; 32(6):539-48. PubMed ID: 3653222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
